Hepatitis D | ScienceGate

Approximately 5% of individuals infected with hepatitis B virus (HBV) are coinfected with hepatitis D virus (HDV). Chronic HBV/HDV coinfection is associated with an unfavourable outcome, with many patients developing liver cirrhosis, liver failure and eventually hepatocellular carcinoma within 5–10 years. The identification of the HBV/HDV receptor and the development of novel in vitro and animal infection models allowed a more detailed study of the HDV life cycle in recent years, facilitating the development of specific antiviral drugs. The characterisation of HDV-specific CD4+ and CD8+T cell epitopes in untreated and treated patients also permitted a more precise understanding of HDV immunobiology and possibly paves the way for immunotherapeutic strategies to support upcoming specific therapies targeting viral or host factors. Pegylated interferon-α has been used for treating HDV patients for the last 30 years with only limited sustained responses. Here we describe novel treatment options with regard to their mode of action and their clinical effectiveness. Of those, the entry-inhibitor bulevirtide (formerly known as myrcludex B) received conditional marketing authorisation in the European Union (EU) in 2020 (Hepcludex). One additional drug, the prenylation inhibitor lonafarnib, is currently under investigation in phase III clinical trials. Other treatment strategies aim at targeting hepatitis B surface antigen, including the nucleic acid polymer REP2139Ca. These recent advances in HDV virology, immunology and treatment are important steps to make HDV a less difficult-to-treat virus and will be discussed.

Download Full-text

Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan

Scientific Reports ◽

10.1038/s41598-021-87975-5 ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Ming-Ying Lu ◽

Chun-Ting Chen ◽

Yu-Lueng Shih ◽

Pei-Chien Tsai ◽

Meng-Hsuan Hsieh ◽

...

Keyword(s):

Hepatitis B ◽

Drug Users ◽

High Risk Group ◽

Health Concern ◽

Hepatitis D ◽

Hcv Genotypes ◽

Hbsag Carriers ◽

Treatment Naïve ◽

Hdv Infection ◽

Hbsag Seropositivity

AbstractThe spreading of viral hepatitis among injecting drug users (IDU) is an emerging public health concern. This study explored the prevalence and the risks of hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis D virus (HDV) among IDU-dominant prisoners in Taiwan. HBV surface antigen (HBsAg), antibodies to HCV (anti-HCV) and HDV (anti-HDV), viral load and HCV genotypes were measured in 1137(67.0%) of 1697 prisoners. 89.2% of participants were IDUs and none had HIV infection. The prevalence of HBsAg, anti-HCV, dual HBsAg/anti-HCV, HBsAg/anti-HDV, and triple HBsAg/anti-HCV/anti-HDV was 13.6%, 34.8%, 4.9%, 3.4%, and 2.8%, respectively. HBV viremia rate was significantly lower in HBV/HCV-coinfected than HBV mono-infected subjects (66.1% versus 89.9%, adjusted odds ratio/95% confidence intervals [aOR/CI] = 0.27/0.10–0.73). 47.5% anti-HCV-seropositive subjects (n = 396) were non-viremic, including 23.2% subjects were antivirals-induced. The predominant HCV genotypes were genotype 6(40.9%), 1a(24.0%) and 3(11.1%). HBsAg seropositivity was negatively correlated with HCV viremia among the treatment naïve HCV subjects (44.7% versus 72.4%, aOR/CI = 0.27/0.13–0.58). Anti-HCV seropositivity significantly increased the risk of anti-HDV-seropositivity among HBsAg carriers (57.1% versus 7.1%, aOR/CI = 15.73/6.04–40.96). In conclusion, IUDs remain as reservoirs for multiple hepatitis viruses infection among HIV-uninfected prisoners in Taiwan. HCV infection increased the risk of HDV infection but suppressed HBV replication in HBsAg carriers. An effective strategy is mandatory to control the epidemic in this high-risk group.

Download Full-text

Chronic Hepatitis D Virus (HDV) Infection in Hepatitis B Virus Carrier Chimpanzees Experimentally Superinfected with HDV

The Journal of Infectious Diseases ◽

10.1093/infdis/158.1.151 ◽

1988 ◽

Vol 158 (1) ◽

pp. 151-159 ◽

Cited By ~ 32

Author(s):

F. Negro ◽

K. F. Bergmann ◽

B. M. Baroudy ◽

W. C. Satterfield ◽

H. Popper ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B Virus ◽

Hepatitis B ◽

Hepatitis D ◽

Hepatitis D Virus ◽

B Virus ◽

Hepatitis B Virus Carrier ◽

Hdv Infection ◽

Virus Carrier

Download Full-text

Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: A study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction

Journal of Gastroenterology and Hepatology ◽

10.1111/j.1440-1746.1998.tb00546.x ◽

1998 ◽

Vol 13 (1) ◽

pp. 57-61 ◽

Cited By ~ 11

Author(s):

YI-HSIANG HUANG ◽

JAW-CHING WU ◽

WEN-YUNG SHENG ◽

TEH-IA HUO ◽

FULL-YOUNG CHANG ◽

...

Keyword(s):

Polymerase Chain Reaction ◽

Diagnostic Value ◽

Chain Reaction ◽

Hepatitis D ◽

Hepatitis D Virus ◽

Polymerase Chain

Download Full-text

Viral hepatitis associated hepatocellular carcinoma on the African continent, the past, present, and future: a systematic review

BMC Cancer ◽

10.1186/s12885-021-08426-y ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Ottovon Bismark Dakurah ◽

Cynthia Raissa Tchuem Tamandjou ◽

Moleen Zunza ◽

Wolfgang Preiser ◽

Tongai Gibson Maponga

Keyword(s):

Hepatocellular Carcinoma ◽

Systematic Review ◽

Hepatitis B ◽

Viral Hepatitis ◽

Web Of Science ◽

African Continent ◽

Inclusion Criteria ◽

Hepatitis D ◽

The Past ◽

B Virus

Abstract Background Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths in Africa. In Africa, the major causes of HCC include chronic infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV). Knowledge of the changes in the incidence of viral hepatitis-associated HCC over time and the factors responsible for such changes is key in informing policies for the prevention of viral hepatitis-associated HCC in Africa. Aim The study aimed to systematically summarize the changes in the prevalence of viral hepatitis among HCC patients and the overall effect of the prevalence of viral hepatitis on the incidence of HCC over the past four decades in Africa (1980–2019). Methods A literature search was conducted in MEDLINE (PubMed), Google Scholar, Science Direct, Scopus, Web of Science, and African wide web for articles published on viral hepatitis-associated HCC in Africa from 1980 to 2019. The abstracts of the articles were screened for eligibility and those meeting the inclusion criteria were retrieved and reviewed. Results A total of 272 studies were included in the analysis. Viral hepatitis-related HCC incidence changed by 1.17% (95% confidence interval (CI): 0.63–1.71, p < 0.001), 0.82% (95% CI: 0.45–1.18, p < 0.001), and 3.34% (95% CI: 2.44–4.25, p < 0.001) for every 1% change in the prevalence of HBV, HCV, and hepatitis D virus (HDV) respectively, per decade. The incidence of HBV-related HCC decreased by − 0.50% (95% CI: − 0.74 – − 0.25, p < 0.001) over the last 40 years, while HCV-related HCC increased. Conclusion Overall, the incidence of viral hepatitis-associated HCC has not declined, mainly due to no decline in the prevalence of HCV, HDV, and the high number of chronic hepatitis B carriers on the African continent. There is an urgent need for the allocation of resources for the implementation of treatment and preventive programs for HBV, HCV, HDV, and HCC in Africa. This systematic review is registered with PROSPERO®, number CRD42020169723.

Download Full-text